Invivyd stock: Biotech grants options to new employees

Invivyd announced on November 3, 2026 that it granted options covering 175,000 shares to seven newly hired non-executive employees. The awards were made on November 1 under the company’s 2026 Inducement Plan as a condition of employment, according to the Invivyd investor release.

Hiring awards add equity exposure

Each option carries an exercise price of 0.5817 US dollars per share, matching Invivyd’s closing price on October 30, 2026. The options vest over four years, with one quarter vesting after the first year and the remainder in equal monthly installments, subject to continued employment.

The options have a 10-year term. The grant is an equity incentive for recruitment rather than a financing transaction, so its immediate significance for investors lies in the potential future increase in shares outstanding if the options are exercised.

Pipeline remains the central catalyst

Invivyd is developing antibody-based protection against serious viral infectious diseases. Its latest investor materials highlight the INVYMAB platform, which combines viral surveillance, predictive modeling and antibody engineering to create monoclonal antibodies against evolving threats.

The company’s pipeline includes VYD2311, which is being studied in clinical programs related to COVID-19 and Long COVID, and VMS063, an investigational antibody candidate for measles treatment and prevention. Invivyd has said that manufacturing scale-up for VMS063 is underway ahead of planned clinical development in 2027.

Business profile

Invivyd is a US biotechnology company focused on discovering, developing and potentially commercializing antibody-derived solutions for infectious diseases. Its work begins with SARS-CoV-2 but also extends to other viral threats, including measles. The company is based in New Haven, Connecticut, and remains in the clinical development phase, making trial progress, regulatory decisions and funding needs important factors for investors.